Il tuo browser è obsoleto

Con un browser aggiornato, l'esperienza di navigazione sul sito Web di Medtronic sarà migliore. Aggiorna il mio browser adesso.

×

Skip to main content

Managed Ventricular Pacing (MVP) Cardiac Device Features

Overview

Mounting evidence suggests that right ventricular pacing is associated with a variety of detrimental effects. Most notably, unnecessary right ventricular pacing can lead to an increase of 8% risk of heart failure death per 10% increase in right ventricular pacing.1  Furthermore, right ventricular pacing is associated with a 1% increase in risk of AF for each 1% increase in cumulative right ventricular pacing.2

Managed Ventricular Pacing (MVP™) reduces unnecessary right ventricular pacing by 99%.3

graph

RISK OF AF2

Reducing unnecessary ventricular pacing has been shown to improve clinical outcomes by reducing the risks of atrial fibrillation (AF)2, 4-6 and heart failure hospitalization (HFH).2,4

Reducing ventricular pacing

How does MVP work?

PR Logic

The Managed Ventricular Pacing (MVP) modes promote intrinsic conduction by reducing unnecessary right ventricular pacing. These modes provide atrial-based pacing with ventricular backup. If AV conduction is lost, the device is designed to switch to DDDR or DDD mode. Periodic conduction checks are performed, and if AV conduction resumes, the device switches back to AAIR or AAI mode.

For detailed information regarding this algorithm, visit MedtronicAcademy.com. This feature can be found in some Medtronic Pacemaker, ICD, and CRT-D devices. 

1

Udo E, et al. Int J Cardiol. 2015;185:95-100.

2

Sweeney MO, et al. Circulation. 2003;107:2932-2937.

3

Gillis AM, Pürerfellner H, Israel CW, et al. Reduction of unnecessary right ventricular pacing due to the managed ventricular pacing (MVP) mode in patients with symptomatic bradycardia. Benefit for both sinus node disease and AV block indications. Presented at HRS 2005 (Abstract AB21-1).

4

Anderson HR, Nielsen JC, Thomsen PEB, et al. Long-term follow-up of patients from a randomised trial of atrial versus ventricular pacing for sick-sinus syndrome. 1997;350:1210-1216.

5

Skanes AC, et al. J Am Coll Cardiol. 2001;38:167-172.

6

Neilsen J, et al. J Am Col Cardiol. 2003;42:614-623.

Medtronic Italia S.p.A. Società a socio unico soggetta ad attività di direzione e coordinamento da parte di Medtronic PLC.
Cap. soc. € 1.200.487,00 - Codice fiscale, partita IVA e numero di iscrizione al Registro delle Imprese di Milano-Monza-Brianza-Lodi 09238800156 – REA MI – 1275682. Sede Legale e Uffici Via Varesina, 162 Edificio Raimondi - 20156 Milano.